Dr. Dan P. Zandberg
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
Expert in Parotid Gland Cancer
Expert in Squamous Cell Carcinoma
20 reported clinical trials
36 drugs studied
Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
p16 positive
2Squamous Cell Carcinoma
Global LeaderStage IV
Stage III
PD-L1 positive
Affiliated Hospitals
Clinical Trials Dan P. Zandberg is currently running
Pembrolizumab + Radiation vs Chemotherapy + Radiation
for Head and Neck Cancer
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting1 award Phase 231 criteria
Targeted Therapy vs. Chemotherapy
for Thyroid Cancer
This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a class of medications called receptor tyrosine kinase inhibitors. It binds to and blocks the action of several enzymes which are often over-expressed in a variety of tumor cell types. This may help stop or slow the growth of tumor cells and blood vessels the tumor needs to survive. Dabrafenib is an enzyme inhibitor that binds to and inhibits the activity of a protein called B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. Trametinib is also an enzyme inhibitor. It binds to and inhibits the activity of proteins called MEK 1 and 2, which play a key role in activating pathways that regulate cell growth. This may inhibit the growth of tumor cells mediated by these pathways. The usual approach for patients with thyroid cancer is targeted therapy with dabrafenib and trametinib. This trial may help researchers decide which treatment option (cabozantinib alone or dabrafenib in combination with trametinib) is safer and/or more effective in treating patients with refractory BRAF V600E-mutated differentiated thyroid cancer.
Recruiting2 awards Phase 37 criteria
More about Dan P. Zandberg
Clinical Trial Related4 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Dan P. Zandberg has experience with
- Cisplatin
- Nivolumab
- Carboplatin
- Pembrolizumab
- Ipilimumab
- Docetaxel
Breakdown of trials Dan P. Zandberg has run
Parotid Gland Cancer
Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Relapse
Neck Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Dan P. Zandberg specialize in?
Is Dan P. Zandberg currently recruiting for clinical trials?
Are there any treatments that Dan P. Zandberg has studied deeply?
What is the best way to schedule an appointment with Dan P. Zandberg?
What is the office address of Dan P. Zandberg?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.